Kininogen-1 (Alpha-2-thiol proteinase inhibitor) (Fitzgerald factor) (High molecular weight kininogen) (HMWK) (Williams-Fitzgerald-Flaujeac factor) [Cleaved into: Kininogen-1 heavy chain; T-kinin (Ile-Ser-Bradykinin); Bradykinin (Kallidin I); Lysyl-bradykinin (Kallidin II); Kininogen-1 light chain; Low molecular weight growth-promoting factor]
1_MKLIT 6_ ILFLC 11_ SRLLL 16_ SLTQE 21_ SQSEE 26_ IDCND 31_ KDLFK 36_ AVDAA 41_ LKKYN 46_ SQNQS 51_ NNQFV 56_ LYRIT 61_ EATKT 66_ VGSDT 71_ FYSFK 76_ YEIKE 81_ GDCPV 86_ QSGKT 91_ WQDCE 96_ YKDAA 101_ KAATG 106_ ECTAT 111_ VGKRS 116_ STKFS 121_ VATQT 126_ CQITP 131_ AEGPV 136_ VTAQY 141_ DCLGC 146_ VHPIS 151_ TQSPD 156_ LEPIL 161_ RHGIQ 166_ YFNNN 171_ TQHSS 176_ LFMLN 181_ EVKRA 186_ QRQVV 191_ AGLNF 196_ RITYS 201_ IVQTN 206_ CSKEN 211_ FLFLT 216_ PDCKS 221_ LWNGD 226_ TGECT 231_ DNAYI 236_ DIQLR 241_ IASFS 246_ QNCDI 251_ YPGKD 256_ FVQPP 261_ TKICV 266_ GCPRD 271_ IPTNS 276_ PELEE 281_ TLTHT 286_ ITKLN 291_ AENNA 296_ TFYFK 301_ IDNVK 306_ KARVQ 311_ VVAGK 316_ KYFID 321_ FVARE 326_ TTCSK 331_ ESNEE 336_ LTESC 341_ ETKKL 346_ GQSLD 351_ CNAEV 356_ YVVPW 361_ EKKIY 366_ PTVNC 371_ QPLGM 376_ ISLMK 381_ RPPGF 386_ SPFRS 391_ SRIGE 396_ IKEET 401_ TVSPP 406_ HTSMA 411_ PAQDE 416_ ERDSG 421_ KEQGH 426_ TRRHD 431_ WGHEK 436_ QRKHN 441_ LGHGH 446_ KHERD 451_ QGHGH 456_ QRGHG 461_ LGHGH 466_ EQQHG 471_ LGHGH 476_ KFKLD 481_ DDLEH 486_ QGGHV 491_ LDHGH 496_ KHKHG 501_ HGHGK 506_ HKNKG 511_ KKNGK 516_ HNGWK 521_ TEHLA 526_ SSSED 531_ STTPS 536_ AQTQE 541_ KTEGP 546_ TPIPS 551_ LAKPG 556_ VTVTF 561_ SDFQD 566_ SDLIA 571_ TMMPP 576_ ISPAP 581_ IQSDD 586_ DWIPD 591_ IQIDP 596_ NGLSF 601_ NPISD 606_ FPDTT 611_ SPKCP 616_ GRPWK 621_ SVSEI 626_ NPTTQ 631_ MKESY 636_YFDLT
1: Kininogens are inhibitors of thiol proteases. HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. LMW-kininogen inhibits the aggregation of thrombocytes. LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting
2: The active peptide bradykinin is a potent vasodilatator that is released from HMW-kininogen shows a variety of physiological effects: (A) influence in smooth muscle contraction, (B) induction of hypotension, (C) natriuresis and diuresis, (D) decrease in blood glucose level, (E) it is a mediator of inflammation and causes (E1) increase in vascular permeability, (E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action)